Welcome to our dedicated page for CORCEPT THERAPEUTICS SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Corcept Therapeutics announced that ROSELLA, its pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its overall survival primary endpoint. This means the treatment combination achieved its main goal of improving how long patients live in this hard-to-treat setting. The company shared this outcome through a press release attached as an exhibit, signaling a key late-stage milestone for relacorilant in oncology.
Corcept Therapeutics Chief Development Officer William Guyer reported option exercises and share sales in company stock. On January 6, 2026, he exercised a stock option for 20,000 shares of common stock at an exercise price of $21.65 per share and then sold 20,000 shares of common stock at a weighted average price of $35.1828 per share. The filing notes that the sale prices ranged from $34.96 to $35.50 per share. These transactions were made under a Rule 10b5-1 trading plan adopted on November 27, 2024. After the transactions, Guyer directly held 1,235 shares of common stock and 250,000 stock options that are reported as fully exercisable.
Corcept Therapeutics Inc. insider plans another share sale. A Form 144 notice discloses an intended sale of up to 20,000 shares of Corcept common stock through Stifel Nicolaus & Company Inc. on or about 01/06/2026, with an indicated aggregate market value of $699,000.00. The filing notes that 105,190,000 Corcept common shares were outstanding, providing context for the size of the planned transaction.
The 20,000 shares to be sold were acquired on 01/06/2026 via a stock option exercise from Corcept Therapeutics Inc., paid in cash. Over the prior three months, the same seller, William Guyer, reported three separate sales of 20,000 Corcept common shares each (on 10/07/2025, 11/05/2025, and 12/02/2025) with gross proceeds of $1,798,781.00, $1,507,121.00, and $1,601,525.00, respectively.
Corcept Therapeutics director James N. Wilson reported several internal movements of Corcept common stock among family-related entities on December 12, 2025. A family trust disposed of 400,000 shares as a gift at a reported price of $0.00 per share, leaving 1,045,168 shares held indirectly through the James N. Wilson and Pamela D. Wilson Trust.
Two 2025 grantor retained annuity trusts each received 200,000 shares without consideration and are reported as indirectly holding 200,000 shares apiece. The report also lists 901,067 shares of Corcept common stock held indirectly through James and Pamela Wilson Family Partners, over which Wilson has voting power pursuant to voting agreements while disclaiming beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics (CORT) Chief Development Officer William Guyer reported transactions on 11/05/2025. He exercised 20,000 stock options at $21.65 and sold a total of 20,000 shares in multiple trades, including 6,536 shares at a weighted average of $74.7489, 13,164 shares at $75.6365, and 300 shares at $76.28. Following these trades, he directly owned 5,287 shares and held 290,000 derivative securities (options) afterward. The transactions were made under a Rule 10b5-1 plan adopted on November 27, 2024.
Corcept Therapeutics (CORT) insider transaction: Chief Accounting & Technology Officer Joseph Douglas Lyon exercised 5,000 stock options at $13.56 per share on 11/03/2025 and sold 5,000 common shares the same day at a weighted average price of $73.6489. The filing notes sale prices ranged from $73.47 to $73.945 per share.
Following these transactions, he beneficially owned 10,277 shares directly. The filing also notes unvested restricted stock awards granted on 12/02/2024 (215 shares), 03/03/2025 (216 shares), 06/02/2025 (749 shares), and 09/02/2025 (200 shares), which vest 100% on the one-year anniversary of each grant, subject to conditions. The option exercised was fully exercisable and relates to a grant expiring 02/07/2030, with 16,571 derivative securities beneficially owned afterward.
The sale was made pursuant to a Rule 10b5-1 trading plan adopted on 08/30/2024.
Corcept Therapeutics (CORT) CEO and director Joseph K. Belanoff reported open‑market sales totaling 40,000 shares pursuant to a Rule 10b5‑1 trading plan adopted on November 26, 2024.
The trades occurred on November 3, 2025 (11,218 shares at $74.0786) and November 5, 2025 (14,355 at $74.196; 10,837 at $75.1372; 3,590 at $75.9777). Following these sales, 2,741,370 shares were beneficially owned indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02.
He has voting power over the trust shares pursuant to voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics (CORT) officer Sean Maduck exercised stock options for 20,000 shares at $8.27 on 11/03/2025, then sold 20,000 shares at a weighted average price of $73.9908. The sale was made pursuant to a Rule 10b5-1 plan adopted on 09/05/2024.
After these transactions, he directly holds 7,904 shares and 261,986 stock options. Indirect holdings are 59,717 shares via the Sean and Molly Maduck Living Trust, 40,000 shares via the SNM 2025 GRAT, and 10,000 shares via Duckhill Capital, LLC.
Corcept Therapeutics (CORT) reported Q3 2025 results. Net product revenue was $207.6 million, up from $182.5 million a year ago, driven by a 42.5% increase in sales volume, partly offset by a 20.2% lower average price due to higher authorized‑generic mix; an August 2025 price increase partially offset the decline. Cost of sales rose to $4.6 million, including a $1.0 million inventory write‑off.
Operating expenses expanded as the company invests behind pipeline and commercialization: R&D was $68.8 million and SG&A was $124.0 million. Income from operations fell to $10.2 million (from $46.6 million). Net income was $19.7 million versus $47.2 million, with diluted EPS of $0.16 versus $0.41. Cash, cash equivalents and marketable securities totaled $524.2 million as of September 30, 2025. Year‑to‑date, the company repurchased 2.6 million shares for $172.9 million; $11.4 million remains authorized. Shares outstanding were 105,188,217 as of October 23, 2025.
Key pipeline milestones: the FDA accepted the NDA for relacorilant in hypercortisolism with a PDUFA date of December 30, 2025, and accepted the NDA for relacorilant plus nab‑paclitaxel in platinum‑resistant ovarian cancer with a PDUFA date of July 11, 2026. A Q3 tax benefit reflected newly enacted U.S. legislation allowing immediate expensing of certain R&D.
Corcept Therapeutics (CORT) furnished an 8-K stating it issued a press release with financial results for the quarter ended September 30, 2025 and a corporate update. The release, dated November 4, 2025, is attached as Exhibit 99.1.
The information under Items 2.02 and 7.01 is furnished, not filed, and is not subject to Section 18 liabilities, nor incorporated by reference unless expressly stated.